+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Next Generation Sequencing (NGS) Market Size, Share & Trends Analysis Report By End Use, By Technology, By Products & Services, By Application, By Workflow, By Region, And Segment Forecasts, 2019 - 2025

  • ID: 4761224
  • Report
  • Region: Global
  • 320 pages
  • Grand View Research
1 of 4

FEATURED COMPANIES

  • BGI
  • DNASTAR, Inc.
  • Genomatix GmbH
  • LGC Limited
  • Myriad Genetics, Inc.
  • Perkin Elmer, Inc.
  • MORE
The global next generation sequencing market is expected to reach USD 19.70 billion by 2025 registering a CAGR of 12.78%, according to this report. Growing application of NGS methodologies due to rising number of strategic developments initiated by the market participants is one of the key drivers of the market. These novel strategies mark the presence of intense competition between the key firms. Companies are further increasing their installation base by providing sequencing services in different emerging countries. For instance, in April 2018, Illumina entered into a partnership with Loxo Oncology for the development of Illumina TruSight Tumor 170 NGS test as a companion diagnostic for Loxo Oncology’s LOXO-292 and larotrectinib for tumor profiling.

Similarly, in March 2018, PierianDx partnered with cancer genetics to offer NGS-based tests for oncology precision medicine. NGS technologies experience significant growth due to rapid automation in the pre-sequencing protocols and advancements in clinical diagnosis and disease testing. Wide application of this technique in oncology, reproductive screening, infectious disease, noninvasive prenatal testing, and pharmacogenomics is also expected to positively impact the market growth. Reduced costs of genetic sequencing has also significantly enhanced the adoption of these technologies. Reduced installation costs of NGS platforms and easy availability of proteomic and genomic data has also resulted in an increased demand, thereby propelling the market development.

key findings from the study suggest:
  • NGS-based platforms & related products account for the dominant market share due to the presence of sequencing platforms and instruments required for clinical applications
  • Growing awareness related to NGS services is likely to boost growth of the services segment
  • Cancer-related genes have a high level of genomic heterogeneity that can be easily detected by NGS, thus resulting in maximum revenue flow from the oncology field
  • On the basis of workflow, sequencing vertical accounted for the largest revenue share of the NGS market in 2018 and is said to continue its dominance over the forecast period
  • High demand for this technology and usage of NGS platforms for several research projects and Ph.D. programs contributes to academic research segment’s growth
  • Whereas, clinical research segment will witness a significant CAGR owing to emergence of NGS applications in clinical research and studies
  • North American held the maximum revenue share in 2018 due to the presence of a number of NGS technology providers, such as Illumina and Thermo Fisher
  • Asia Pacific is expected to emerge as the fastest-growing region due to continuous improvements laid by key participants in emerging economies, such as China and India
  • Prominent companies in the global market include Illumina Inc.; QIAGEN; F Hoffman-La Roche Ltd.; Thermo Fisher Scientific Inc.; and Bio-Rad Laboratories, Inc.
  • Product development and M&A are some of the key strategies adopted by these companies, for instance, Illumina acquired Edico Genome to improve the overall efficiency of NGS solutions provided by Illumina


Please Note: This report will be delivered within 2 business day of ordering.
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • BGI
  • DNASTAR, Inc.
  • Genomatix GmbH
  • LGC Limited
  • Myriad Genetics, Inc.
  • Perkin Elmer, Inc.
  • MORE
Chapter 1 Research Methodology & Scope
1.1 Information Procurement
1.1.1 Purchased database:
1.1.2 Internal database
1.1.3 Secondary sources:
1.1.4 Third Party Perspective:
1.1.5 Primary Research:
1.2 Information or Data Analysis
1.3 Market Formulation & Validation
1.4 Region Wise Market Calculation
1.4.1 Region wise market: Base estimates
1.4.2 Global market: CAGR calculation
1.4.3 Region based segment share calculation

Chapter 2 Executive Summary
2.1 Next Generation Sequencing Market Outlook, 2014 - 2025
2.2 Next Generation Sequencing Market : Segment Outlook, 2014 - 2025
2.3 Next Generation Sequencing Market : Competitive Insights

Chapter 3 Next Generation Sequencing Market Variables, Trends, & Scope
3.1 Market Lineage Outlook
3.1.1 Parent market outlook
3.1.2 Related/ancillary market outlook
3.2 Penetration & Growth Prospect Mapping for Applications, 2018
3.3 Penetration & Growth Prospect Mapping for Prominent Industry Players, 2018
3.4 Product Pipeline Analysis, by Stage
3.5 Cost Structure Analysis
3.6 User Perspective Analysis
3.6.1 Consumer behavior analysis
3.6.2 Market influencer analysis
3.7 Procedure Cost Analysis
3.8 End-use analysis
3.9 Technology Overview
3.9.1 Technology timeline
3.10 Regulatory Framework
3.10.1 Next generation sequencing reimbursement scenario
3.10.1.1 Gap fill approach for reimbursement of NGS tests
3.10.1.2 Role of the commercial payers
3.10.1.2.1 Payer perspectives for developing coverage policy for Next Generation Tumor Sequencing Panels (NGTS)
3.10.1.2.2 Role of diagnostic laboratories and pathology centres
3.10.1.3 North America
3.10.1.3.1 U.S.
3.10.1.3.2 Canada
3.10.1.4 Europe
3.10.1.4.1 U.K.
3.10.1.4.2 Germany
3.10.1.4.3 Spain
3.10.1.5 Asia Pacific
3.10.1.6 Latin America
3.10.1.7 Middle East Africa
3.10.2 Next generation sequencing regulatory scenario
3.11 Next Generation Sequencing Market - Market Dynamics
3.11.1 Market driver analysis
3.11.1.1 Exponentially decreasing costs for genetic sequencing
3.11.1.2 Development of companion diagnostics and personalized medicine
3.11.1.3 Rise in competition amongst prominent market entities
3.11.1.4 Rising clinical opportunity for NGS technology
3.11.1.5 Technological advancements in cloud computing and data integration
3.11.1.6 Growing healthcare expenditure supporting development of effective PM diagnostic & therapeutic procedures for cancer
3.11.1.7 Increasing prevalence of cancer
3.11.2 Market restraint analysis
3.11.2.1 Lack of computational efficiency for data management
3.11.2.2 Non-value based NGS reimbursement policy and regulation status
3.11.3 Market challenges analysis
3.11.3.1 Effective analysis of vast data generated through NGS
3.12 Next Generation Sequencing Market Analysis Tools
3.12.1 Industry Analysis - Porter’s
3.12.1.1 Supplier power : Complexity of NGS products results in low supplier bargaining power
3.12.1.2 Buyer power: Low buyer power is observed as they have lesser power to influence the price
3.12.1.3 Substitution threat: Low threat of substitution owing to highly specific nature of genome sequencing
3.12.1.4 New entrants threat: Threat of new entrant is low due presence of few dominant players
3.12.1.5 Competitive rivalry: High competitive rivalry due to launch of novel NGS technologies
3.12.2 PESTEL analysis
3.12.2.1 Political landscape
3.12.2.2 Environmental landscape
3.12.2.3 Social landscape
3.12.2.4 Technology landscape
3.12.2.5 Legal landscape
3.12.3 Major deals & strategic alliances analysis
3.12.3.1 Joint ventures
3.12.3.2 Mergers & acquisitions
3.12.3.3 Licensing & partnership
3.12.3.4 Technology collaborations
3.12.3.5 Strategic divestments
3.12.4 Market entry strategies
3.12.5 Case studies
3.13 NGS Platform Penetration Mapping, 2018
3.13.1 Next Generation Sequencing Market: Regional Market Share, 2018
3.13.2 Next Generation Sequencing North America Regulatory and Political Landscape Analysis, 2018
3.13.2.1 U.S.
3.13.2.2 Canada
3.13.3 Next Generation Sequencing Europe Regulatory and Political Landscape Analysis, 2018
3.13.3.1 U.K.
3.13.3.2 Germany
3.13.3.3 France
3.13.3.4 Spain
3.13.4 Next Generation Sequencing Asia Pacific Regulatory and Political Landscape Analysis, 2018
3.13.4.1 Japan
3.13.4.2 China
3.13.5 Next Generation Sequencing Latin America Regulatory and Political Landscape Analysis, 2018
3.13.5.1 Brazil
3.13.5.2 Mexico
3.13.5.3 Argentina
3.13.6 Next Generation Sequencing Middle East & Africa Regulatory and Political Landscape Analysis, 2018
3.13.6.1 South Africa
3.13.6.2 Qatar
3.13.6.3 Kuwait
3.13.6.4 UAE
3.13.6.5 Saudi Arabia

Chapter 4 Next Generation Sequencing Market: Competitive Analysis
4.1 Recent Developments & Impact Analysis, by Key Market Participants
4.2 Company/Competition Categorization
4.3 Vendor Landscape
4.3.1 List of key distributors and channel partners
4.3.2 Key customers
4.3.3 Key company market share analysis, 2018
4.3.4 Public Companies
4.3.4.1 Company market position analysis
4.3.4.2 Company market share/ranking by region
4.3.4.3 Competitive dashboard analysis
4.3.4.4 Market differentiators
4.3.4.5 Synergy analysis: Major deals & strategic alliances
4.3.5 Private Companies
4.3.5.1 List of key emerging companies
4.3.5.2 Funding outlook
4.3.5.3 Regional network map
4.3.5.4 Company market position analysis
4.3.5.5 Supplier Ranking

Chapter 5 Next Generation Sequencing Market Categorization: Products and Services Estimates & Trend Analysis
5.1 Definitions & Scope
5.2 Products and Services Market Share Analysis, 2018 & 2025
5.3 Next Generation Sequencing Market: Products and Services Movement Analysis, 2018 & 2025
5.4 Global Next Generation Sequencing Market, by Products and Services, 2014 to 2025
5.5 Market Size & Forecasts and Trend Analyses, 2014 to 2025 for the following
5.5.1 NGS Platforms and Related Products
5.5.1.1 NGS platforms & related products market, 2014 - 2025 (USD Million)
5.5.2 NGS Services
5.5.2.1 NGS services market, 2014 - 2025 (USD Million)
5.6 Next Generation Sequencing Product and Services Market, by Application, 2014 to 2025

Chapter 6 Next Generation Sequencing Market Categorization: Application Estimates & Trend Analysis
6.1 Definitions & Scope
6.2 Application Market Share Analysis, 2018 & 2025
6.3 Next Generation Sequencing Market: Application Movement Analysis, 2018 & 2025
6.4 Global Next Generation Sequencing Market, by Application, 2014 to 2025
6.5 Market Size & Forecasts and Trend Analyses, 2014 to 2025 for the following,
6.5.1 Oncology
6.5.1.1 Global oncology market, 2014 - 2025 (USD Million)
6.5.1.2 Diagnostics and screening
6.5.1.2.1 Diagnostics and screening market, 2014 - 2025 (USD Million)
6.5.1.2.2 Oncology screening
6.5.1.2.2.1 Oncology screening market, 2014 - 2025 (USD Million)
6.5.1.2.2.2 Sporadic cancer screening market, 2014 - 2025 (USD Million)
6.5.1.2.2.3 Inherited cancer screening market, 2014 - 2025 (USD Million)
6.5.1.2.3 Companion diagnostics market, 2014 - 2025 (USD Million)
6.5.1.2.4 Other diagnostics market, 2014 - 2025 (USD Million)
6.5.1.3 Research studies market, 2014 - 2025 (USD Million)
6.5.2 Clinical investigation
6.5.2.1 Global clinical investigation market, 2014 - 2025 (USD Million)
6.5.2.2 Infectious diseases
6.5.2.2.1 Global infectious diseases market, 2014 - 2025 (USD Million)
6.2.2.3 Inherited diseases
6.5.2.3.1 Global inherited diseases market, 2014 - 2025 (USD Million)
6.2.2.4 Idiopathic diseases
6.5.2.4.1 Global idiopathic diseases market, 2014 - 2025 (USD Million)
6.5.2.5 Non-communicable/other diseases
6.5.2.5.1 Global non-communicable/other diseases market, 2014 - 2025 (USD Million)
6.5.3 Reproductive health
6.5.3.1 Global reproductive health market, 2014 - 2025 (USD Million)
6.5.3.2 NIPT
6.5.3.2.1 Global NIPT market, 2014 - 2025 (USD Million)
6.5.3.2.2 Global aneuploidy market, 2014 - 2025 (USD Million)
6.5.3.2.3 Global microdeletions market, 2014 - 2025 (USD Million)
6.5.3.3 PGT
6.5.3.3.1 Global NGS PGT market, 2014 - 2025 (USD Million)
6.5.3.4 New-born/genetic screening
6.5.3.4.1 Global newborn/genetic screening market, 2014 - 2025 (USD Million)
6.5.3.5 Single gene analysis
6.5.3.5.1 Single gene analysis market, 2014 - 2025 (USD Million)
6.5.4 HLA typing/immune system monitoring
6.5.4.1 Global HLA typing/immune system monitoring market, 2014 - 2025 (USD Million)
6.5.5 Metagenomics, epidemiology & drug development
6.5.5.1 Global metagenomics, epidemiology & drug development market, 2014 - 2025 (USD Million)
6.5.6 Agrigenomics & forensics
6.5.6.1 Global agrigenomics & forensics market, 2014 - 2025 (USD Million)
6.5.7 Consumer genomics
6.5.7.1 Global consumer genomics market, 2014 - 2025 (USD Million)

Chapter 7 Next Generation Sequencing Market Categorization: Technology Estimates & Trend Analysis
7.1 Definitions & Scope
7.2 Technology Market Share Analysis, 2018 & 2025
7.3 Next Generation Sequencing Market: Technology Movement Analysis, 2018 & 2025
7.4 Global Next Generation Sequencing Market, by Technology, 2014 to 2025
7.5 Market Size & Forecasts and Trend Analyses, 2014 to 2025 for the following,
7.5.1 Whole genome sequencing
7.5.1.1 Global whole genome sequencing market, 2014 - 2025 (USD Million)
7.5.2 Whole exome sequencing
7.5.2.1 Global whole exome sequencing market, 2014 - 2025 (USD Million)
7.5.3 Targeted sequencing & resequencing
7.5.3.1 Global targeted sequencing & resequencing market, 2014 - 2025 (USD Million)
7.5.3.1.1 DNA based targeted sequencing & resequencing
7.5.3.1.2 Global DNA based targeted sequencing & resequencing market, 2014 - 2025 (USD Million)
7.5.3.2 RNA-based targeted sequencing & resequencing
7.5.3.2.1 Global RNA based targeted sequencing & resequencing market, 2014 - 2025 (USD Million)

Chapter 8 Next Generation Sequencing Market Categorization: Workflow Estimates & Trend Analysis
8.1 Definitions & Scope
8.2 Workflow Market Share Analysis, 2018 & 2025
8.3 Next Generation Sequencing Market: Workflow Movement Analysis, 2018 & 2025
8.4 Global Next Generation Sequencing Market by Workflow, 2018 & 2025
8.5 Market Size & Forecasts and Trend Analyses, 2014 to 2025 for the following,
8.5.1 Pre-Sequencing
8.5.1.1 Global pre-sequencing market, 2014 - 2025 (USD Million)
8.5.1.2 NGS library preparation kits
8.5.1.2.1 Global NGS library preparation kits market, 2014 - 2025 (USD Million)
8.5.1.3 NGS semi-automated library preparation
8.5.1.3.1 Global NGS semi-automated library preparation market, 2014 - 2025 (USD Million)
8.5.1.4 NGS automated library preparation
8.5.1.4.1 Global NGS automated library preparation market, 2014 - 2025 (USD Million)
8.5.1.5 Clonal amplification
8.5.1.5.1 Global clonal amplification market, 2014 - 2025 (USD Million)
8.5.2 Sequencing
8.5.2.1 Global sequencing market, 2014 - 2025 (USD Million)
8.5.3 Data analysis
8.5.3.1 Global data analysis market, 2014 - 2025 (USD Million)
8.5.3.2 NGS primary data analysis
8.5.3.2.1 Global NGS primary data analysis market, 2014 - 2025 (USD Million)
8.5.3.3 NGS secondary data analysis
8.5.3.3.1 Global NGS secondary data analysis market, 2014 - 2025 (USD Million)
8.5.3.4 NGS tertiary data analysis
8.5.3.4.1 Global NGS tertiary data analysis services market, 2014 - 2025 (USD Million)

Chapter 9 Next Generation Sequencing Market Categorization: End-use Estimates & Trend Analysis
9.1 Definitions & Scope
9.2 End-use Market Share Analysis, 2018 & 2025
9.3 Next Generation Sequencing Market: End-Use Movement Analysis, 2018 & 2025
9.4 Global Next Generation Sequencing Market, by End-use, 2014 to 2025
9.5 Market Size & Forecasts and Trend Analyses, 2014 to 2025 for the following,
9.5.1 Academic research
9.5.1.1 Global academic research market, 2014 - 2025 (USD Million)
9.5.2 Clinical research
9.5.2.1 Global clinical research market, 2014 - 2025 (USD Million)
9.5.3 Hospitals & clinics
9.5.3.1 Global hospitals & clinics market2014 - 2025 (USD Million)
9.5.4 Pharma & biotech entities
9.5.4.1 Global pharma & biotech entities market, 2014 - 2025 (USD Million)
9.5.5 Other users
9.5.5.1 Global other users market, 2014 - 2025 (USD Million)

Chapter 10 Next Generation Sequencing Market Categorization: Regional Estimates & Trend Analysis, by Product & Service Type, Application, Technology, Workflow, & End-use
10.1 Next generation sequencing market share by region, 2018 & 2025
10.2 Regional Market Share and Leading Players, 2018
10.2.1 North America
10.2.2 Europe
10.2.3 Asia Pacific
10.2.4 Latin America
10.2.5 Middle East & Africa
10.3 North America
10.3.1 North America next generation sequencing market, 2014 - 2025 (USD Million)
10.3.2 U.S.
10.3.2.1 U.S. next generation sequencing market, 2014 - 2025 (USD Million)
10.3.3 Canada
10.3.3.1 Canada next generation sequencing market, 2014 - 2025 (USD Million)
10.4 Europe
10.4.1 Europe next generation sequencing market, 2014 - 2025 (USD Million)
10.4.2 Germany
10.4.2.1 Germany next generation sequencing market, 2014 - 2025 (USD Million)
10.4.3 U.K.
10.4.3.1 U.K. next generation sequencing market, 2014 - 2025 (USD Million)
10.5 Asia Pacific
10.5.1 Asia Pacific next generation sequencing market, 2014 - 2025 (USD Million)
10.5.2 Japan
10.5.2.1 Japan next generation sequencing market, 2014 - 2025 (USD Million)
10.5.3 China
10.5.3.1 China next generation sequencing market, 2014 - 2025 (USD Million)
10.6 Latin America
10.6.1 Latin America next generation sequencing market, 2014 - 2025 (USD Million)
10.6.2 Brazil
10.6.2.1 Brazil next generation sequencing market, 2014 - 2025 (USD Million)
10.7 Middle East & Africa
10.7.1 Middle East & Africa next generation sequencing market, 2014 - 2025 (USD Million)
10.7.2 South Africa
10.7.2.1 South Africa next generation sequencing market, 2014 - 2025 (USD Million)

Chapter 11 Competitive Landscape
11.1 Strategy Framework
11.2 Market Participation Categorization
11.3 Next-Generation Sequencing Vendor’s Landscape
11.3.1 Champions
11.3.2 Innovators
11.3.3 Emerging players
11.3.4 Market pillars
11.4 Company Profiles
11.4.1 Illumina, Inc.
11.4.1.1 Company overview
11.4.1.2 Financial performance
11.4.1.3 Product benchmarking
11.4.1.4 Strategic initiatives
11.4.2 F. Hoffmann-La Roche Ltd.
11.4.2.1 Company overview
11.4.2.2 Financial performance
11.4.2.3 Product benchmarking
11.4.2.4 Strategic initiatives
11.4.3 Agilent Technologies, Inc.
11.4.3.1 Company overview
11.4.3.2 Financial performance
11.4.3.3 Product benchmarking
11.4.3.4 Strategic initiatives
11.4.4 PierianDx
11.4.4.1 Company overview
11.4.4.1.1 Tute Genomics
11.4.4.1.2 Knome, Inc.
11.4.4.2 Financial performance
11.4.4.3 Product benchmarking
11.4.4.4 Strategic initiatives
11.4.5 Genomatix GmbH
11.4.5.1 Company overview
11.4.5.2 Financial performance
11.4.5.3 Product benchmarking
11.4.5.4 Strategic initiatives
11.4.6 Eurofins GATC Biotech GmbH
11.4.6.1 Company overview
11.4.6.2 Financial performance
11.4.6.3 Product benchmarking
11.4.6.4 Strategic initiatives
11.4.7 Oxford Nanopore Technologies
11.4.7.1 Company overview
11.4.7.2 Financial performance
11.4.7.3 Product benchmarking
11.4.7.4 Strategic initiatives
11.4.8 Macrogen, Inc.
11.4.8.1 Company overview
11.4.8.2 Financial performance
11.4.8.3 Product benchmarking
11.4.8.4 Strategic initiatives
11.4.9 Thermo Fisher Scientific, Inc.
11.4.9.1 Company overview
11.4.9.1.1 Life Technologies Corp.
11.4.9.2 Financial performance
11.4.9.3 Product benchmarking
11.4.9.4 Strategic initiatives
11.4.10 DNASTAR, Inc.
11.4.10.1 Company overview
11.4.10.2 Financial Performance
11.4.10.3 Product benchmarking
11.4.10.4 Strategic initiatives
11.4.11 Biomatters Ltd.
11.4.11.1 Company overview
11.4.11.2 Financial performance
11.4.11.3 Product benchmarking
11.4.11.4 Strategic initiatives
11.4.12 QIAGEN
11.4.12.1 Company overview
11.4.12.1.1 Ingenuity
11.4.12.1.2 CLC Bio
11.4.12.2 Financial performance
11.4.12.3 Product benchmarking
11.4.12.4 Strategic initiatives
11.4.13 BGI
11.4.13.1 Company overview
11.4.13.1.1 Complete Genomics Incorporated
11.4.13.2 Financial performance
11.4.13.3 Product benchmarking
11.4.13.4 Strategic initiatives
11.4.14 Perkin Elmer, Inc.
11.4.14.1 Company overview
11.4.14.2 Financial performance
11.4.14.3 Product benchmarking
11.4.14.4 Strategic initiatives
11.4.15 Pacific Biosciences of California, Inc.
11.4.15.1 Company overview
11.4.15.2 Financial performance
11.4.15.3 Product benchmarking
11.4.15.4 Strategic initiatives
11.4.16 Partek Incorporated
11.4.16.1 Company overview
11.4.16.2 Financial performance
11.4.16.3 Product benchmarking
11.4.16.4 Strategic initiatives
11.4.17 Bio-Rad Laboratories, Inc.
11.4.17.1 Company overview
11.4.17.2 GnuBio
11.4.17.2.1 Company overview
11.4.17.3 Financial performance
11.4.17.4 Product benchmarking
11.4.17.5 Strategic initiatives
11.4.18 Myriad Genetics, Inc.
11.4.18.1 Company overview
11.4.18.2 Financial performance
11.4.18.3 Product benchmarking
11.4.18.4 Strategic initiatives
11.4.19 Hologic, Inc. (Gen-Probe Incorporated)
11.4.19.1 Company overview
11.4.19.2 Financial performance
11.4.19.3 Product benchmarking
11.4.19.4 Strategic initiatives
11.4.20 Horizon Discovery Group plc
11.4.20.1 Company overview
11.4.20.2 Financial performance
11.4.20.3 Product benchmarking
11.4.20.4 Strategic initiatives
11.4.21 LGC Limited
11.4.21.1 Company overview
11.4.21.2 SeraCare
11.4.21.2.1 Company overview
11.4.21.3 Financial performance (LGC Limited)
11.4.21.3.1 Financial performance
11.4.21.4 Product benchmarking
11.4.21.5 Strategic initiatives
11.4.22 Vela Diagnostics
11.4.22.1 Company overview
11.4.22.2 Financial performance
11.4.22.3 Product benchmarking
11.4.22.4 Strategic initiatives
11.5 List of Companies

*Full List of Tables and Figures Available on Enquiry.
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • Illumina, Inc.
  • F. Hoffmann-La Roche Ltd.
  • Agilent Technologies, Inc.
  • PierianDx
  • Genomatix GmbH
  • Eurofins GATC Biotech GmbH
  • Oxford Nanopore Technologies
  • Macrogen, Inc.
  • Thermo Fisher Scientific, Inc.
  • DNASTAR, Inc.
  • Biomatters Ltd.
  • QIAGEN
  • BGI
  • Perkin Elmer, Inc.
  • Pacific Biosciences of California, Inc.
  • Partek Incorporated
  • Bio-Rad Laboratories, Inc.
  • Myriad Genetics, Inc.
  • Hologic, Inc. (Gen-Probe Incorporated)
  • Horizon Discovery Group plc
  • LGC Limited
  • Vela Diagnostics
Note: Product cover images may vary from those shown
5 of 4
Note: Product cover images may vary from those shown
Order Online - visit: https://www.researchandmarkets.com/reports/4761224
Adroll
adroll